Logo

Astellas and Seagen's Padcev (enfortumab vedotin) Receive MHLW's Approval for the Treatment of Radically Unresectable Urothelial Carcinoma

Share this

Astellas and Seagen's Padcev (enfortumab vedotin) Receive MHLW's Approval for the Treatment of Radically Unresectable Urothelial Carcinoma

Shots:

  • The approval is based on the P-III EV-301 clinical trial evaluating Padcev vs CT in 608 patients with LA/mUC prior treated with Pt-based CT and a PD-1/L1 inhibitor
  • The pre-specified interim analysis showed that patients treated with Padcev demonstrated an m-OS (12.9 vs 9.0mos.) with a median of 3.9mos. longer than those who received CT
  • Padcev is the first ADC which is approved in Japan for UC. Additionally- nonclinical data showed an anticancer activity due to its binding to Nectin-4 expressing cells followed by internalization and release of anti-tumor agent MMAE into the cell that resulted in cell cycle arrest & cell death

  | Ref: Seagen | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions